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Background
The diversity of HIV-1 is a confounding problem for vac-
cine design, as the human immune response appears to
favour strain specific responses to any given HIV-1 virus
strain. A significant portion of this diversity is manifested
as sequence variability in the loops of HIV-1's surface
envelope glycoprotein. The observation of strain specific
responses suggests that these loops are structurally (sero-
typically) variable between strains. However, the existence
of cross-strain neutralizing antibodies suggests there may
be room for serotypic conservation in the V3 loop.
Methods
6,010 HIV-1 V3 loop sequences were collected from the
Los Alamos National Laboratory database and were ana-
lyzed for variability at individual positions. Variability
was averaged over structurally relevant zones and mapped
on to the mAb 2219 bound HIV-1 MN conformation for
visualization.
Results
Our results indicate that the most variable sequence posi-
tions in the third variable (V3) loop crown cluster to a
small zone on the surface of one face of a β-hairpin con-
formation. These results provide a novel visualization of
gp120 variable loops, specifically demonstrating a pre-
ponderance of conserved three-dimensional structure in a
sequence variable loop.
Conclusion
From a structural point of view, there appears to be plenty
of room for serotypic conservation in this region of the
major neutralizing determinant of this pathogen.
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